Literature DB >> 4020460

Subarachnoid hemorrhage of unknown origin: prognosis and prognostic factors.

J Brismar, G Sundbärg.   

Abstract

The cases of 127 consecutive patients with subarachnoid hemorrhage (SAH), in whom cerebral panangiography revealed no cause for the bleeding nor any sign of an intraparenchymatous hemorrhage, were reviewed in a study of the long-term prognosis and the possible prognostic factors in this condition. Data for all 127 patients in the study were obtained, with an average follow-up period of 5.4 years. After the 1st week post-SAH, only three rebleeds had occurred. In all, 80% of the patients had returned to full activity, 91% to at least part-time work; if the patients with hypertension were excluded, these figures rose to 86% and 95%, respectively. Decreased wakefulness on admission related to a slightly poorer prognosis, whereas age and red blood cell count in the cerebrospinal fluid had no prognostic significance. Of those patients who, at the end of the 2nd week following the SAH, were fully awake and had not developed any symptoms of delayed cerebral ischemia (87% of all patients admitted), 88% returned to full activity, 97% to at least part-time work. The survival rate for this group, as well as causes of death, seem to be within the range for normal individuals. It should thus be possible to inform these patients (at least the normotensive ones) of the benignity of their condition, directly after normal angiography. Even among the patients who were able to return to full activity, symptoms attributable to the SAH were common: 22% experienced problems such as frequent headaches, vertigo, irritability, and increased fatigability.

Entities:  

Mesh:

Year:  1985        PMID: 4020460     DOI: 10.3171/jns.1985.63.3.0349

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  17 in total

1.  Subarachnoid hemorrhage of unknown origin. Longterm prognosis.

Authors:  H M Mehdorn; U Dietrich; R Kalff; B Hoffmann; F Rauhut; W Grote
Journal:  Neurosurg Rev       Date:  1992       Impact factor: 3.042

2.  Subarachnoid haemorrhage of unknown origin: clinical and tomographical aspects.

Authors:  F Cioffi; A Pasqualin; P Cavazzani; R Da Pian
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

3.  The negative angiogram in subarachnoid haemorrhage.

Authors:  H Duong; D Melançon; D Tampieri; R Ethier
Journal:  Neuroradiology       Date:  1996-01       Impact factor: 2.804

Review 4.  Management of subarachnoid haemorrhage.

Authors:  T A Kopitnik; D S Samson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

5.  Subarachnoid haemorrhage of unknown cause: a long term follow-up.

Authors:  T D Hawkins; C Sims; R Hanka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

6.  Perimesencephalic and nonperimesencephalic subarachnoid haemorrhages with negative angiograms.

Authors:  P Canhão; J M Ferro; A N Pinto; T P Melo; J G Campos
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

7.  The value of MRI in angiogram-negative intracranial haemorrhage.

Authors:  S A Renowden; A J Molyneux; P Anslow; J V Byrne
Journal:  Neuroradiology       Date:  1994-08       Impact factor: 2.804

8.  Clinical and long-term follow-up study in patients with spontaneous subarachnoid haemorrhage of unknown aetiology.

Authors:  S Kawamura; N Yasui
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

9.  Morphometric and ultrastructural analysis of the effect of bromocriptine and cyclosporine on the vasospastic femoral artery of rats.

Authors:  Mehmet Tokmak; Kahan Başocak; Hüseyin Canaz; Gökhan Canaz; Celal İplikçioğlu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Is there a difference in cognitive deficits after aneurysmal subarachnoid haemorrhage and subarachnoid haemorrhage of unknown origin?

Authors:  B O Hütter; J M Gilsbach; I Kreitschmann
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.